FATE Company Profile and Key Details
NASDAQ : FATE
Fate Therapeutics
$1.22
0.09+7.96%
At Close 4:00 PM58.9
BESG ScoreESG Rating
Price Chart
Stock Price Today
Fate Therapeutics, Inc. (FATE) stock surged +7.96%, trading at $1.22 on NASDAQ, up from the previous close of $1.13. The stock opened at $1.15, fluctuating between $1.15 and $1.29 in the recent session.
Stock Snapshot
1.13
Prev. Close
141.84M
Market Cap
1.15
Day Low
-1.06
P/E Ratio
-1.15
EPS (TTM)
-1.4
Cash Flow per Share
1.15
Open
116.26M
Number of Shares
1.285
Day High
87.4%
Free Float in %
3.74
Book Value
2.04M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 25, 2026 | 1.15 | 1.29 | 1.15 | 1.22 | 2.04M |
| Mar 24, 2026 | 1.13 | 1.17 | 1.11 | 1.13 | 1.18M |
| Mar 23, 2026 | 1.11 | 1.23 | 1.11 | 1.15 | 1.51M |
| Mar 20, 2026 | 1.09 | 1.13 | 1.07 | 1.10 | 3.42M |
| Mar 19, 2026 | 1.06 | 1.10 | 1.04 | 1.08 | 1.34M |
| Mar 18, 2026 | 1.13 | 1.14 | 1.05 | 1.06 | 1.51M |
| Mar 17, 2026 | 1.18 | 1.19 | 1.13 | 1.13 | 1.26M |
| Mar 16, 2026 | 1.17 | 1.20 | 1.15 | 1.16 | 880.31K |
| Mar 13, 2026 | 1.18 | 1.22 | 1.11 | 1.17 | 1.86M |
| Mar 12, 2026 | 1.23 | 1.26 | 1.17 | 1.17 | 1.02M |
| Mar 11, 2026 | 1.29 | 1.29 | 1.21 | 1.23 | 1.36M |
| Mar 10, 2026 | 1.33 | 1.38 | 1.29 | 1.29 | 1.23M |
| Mar 09, 2026 | 1.32 | 1.38 | 1.28 | 1.33 | 1.36M |
| Mar 06, 2026 | 1.34 | 1.37 | 1.26 | 1.33 | 1.76M |
| Mar 03, 2026 | 1.45 | 1.45 | 1.33 | 1.37 | 1.44M |
| Mar 02, 2026 | 1.41 | 1.51 | 1.41 | 1.50 | 1.18M |
| Feb 27, 2026 | 1.55 | 1.60 | 1.44 | 1.48 | 1.6M |
| Feb 26, 2026 | 1.46 | 1.58 | 1.39 | 1.56 | 2.36M |
| Feb 25, 2026 | 1.62 | 1.70 | 1.48 | 1.48 | 2.33M |
| Feb 24, 2026 | 1.51 | 1.67 | 1.49 | 1.62 | 3.58M |
Contact Details
About Company
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Company Information
| Employees | 181 |
| Beta | 2.23 |
| Sales or Revenue | $63.53M |
| 5Y Sales Change% | 6.654% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
REGN
7.78+1.05%
Regeneron Pharmaceuticals, Inc.$749.47ARGX19.55+2.89%
argenx SE$697.05UTHR9.78+1.84%
United Therapeutics Corporation$541.60MDGL16.89+3.80%
Madrigal Pharmaceuticals, Inc.$461.93VRTX6.35+1.42%
Vertex Pharmaceuticals Incorporated$454.97KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY20.65+6.70%
Alnylam Pharmaceuticals, Inc.$328.70PRAX17.27+5.86%
Praxis Precision Medicines, Inc.$311.92KRYS7.86+3.18%
Krystal Biotech, Inc.$254.95SGEN-0.16-0.07%
Seagen Inc.$228.74Company Overview
Fate Therapeutics, Inc. (NASDAQ:FATE) closed at $1.22 USD, gaining $0.09 (7.96%) from the previous close of $1.13. The stock is currently mid-range between its 52-week high and low $0.66 and $1.94. With a market capitalization of about $141.84 million, Fate Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.23). Key stats such as the average daily volume over the past year has been around 1.65 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Fate Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bahram Valamehr, the company employs approximately 181 people and listed since October 01, 2013. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
Technical Performance
FATE has shown mixed momentum, gaining 2.8% over the past week and -25.17% over the past quarter, though year-to-date performance is up 11.95%. Short-term trend indicators are mixed aligned (SMA20 21.5%, SMA50 34.1%, SMA200 33.46%). The stock’s 14-day RSI is 66.51 (firm momentum), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.58% below its high and over 135.99% above its low. Average 10-day trading volume of 1.64 million shares is in line with the 3-month average of 1.63 million, indicating normal recent market interest.
Dividend & Fair Value
Fate Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.57. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Fate Therapeutics, Inc. generated EPS of -$1.32 over the past year. Five-year average earnings growth is -2.63%. Wall Street analysts project EPS growth of 10.62% annually over the next five years. The latest quarter delivered EPS of -$0.27. The next quarter is forecast at -$0.27. Next year's EPS is expected at -$16.59. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $2.50. The high target offers 473.77% upside. The low target suggests 104.92% downside. The mean target is $4.83. This offers 295.9% upside. Fate Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 13, 2025, missed forecasts by -6.9%. The prior quarter beat by -17.14%. Over the last six quarters, Apple has recorded several small beats. These include -29.79% in August 13, 2024.
Shareholding & Insider Activity
Fate Therapeutics, Inc. has 115.33 million shares outstanding. The public float is 100.80 million shares, elevated short interest at 9.24% of float. This equals 9.28 million shares. The short ratio is 6.34 days. Institutional investors hold 80.04% of the float. Insiders own 1.71%. Redmile Group, LLC holds 12.49 million shares, TAHL CINDY has 387.08 thousand shares and Wolchko J Scott has 371.25 thousand shares. Over the past six months, insider transactions show net selling. They sold 15.78 thousand shares across 2 transactions.
Financial & Profitability Overview
On valuation metrics, Fate Therapeutics trades at a P/E of -1.07, P/S of 21.43 and P/B of 0.70. The current ratio is 5.79 and quick ratio is 5.79. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -266.19 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.38, supported by a cash flow-to-debt ratio of -1.36.
Quarterly Financial Highlights
The company ended the quarter with $315.18M in cash and short-term investments, a total debt of $103.54M, and net debt of $61.67M. Total assets were $506.22M, with equity of $368.42M. Financials further reflected weakness, with operating cash flow of - $132.26M, free cash flow of - $138.42M, and capital expenditures of - $6.15M.
Frequently Asked Questions
What is the current Fate Therapeutics, Inc. (FATE) stock price?
Fate Therapeutics, Inc. (NASDAQ: FATE) stock price is $1.22 in the last trading session. During the trading session, FATE stock reached the peak price of $1.29 while $1.15 was the lowest point it dropped to. The percentage change in FATE stock occurred in the recent session was 7.96% while the dollar amount for the price change in FATE stock was $0.09.
FATE's industry and sector of operation?
The NASDAQ listed FATE is part of Biotechnology industry that operates in the broader Healthcare sector. Fate Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of FATE?
Dr. Bahram Valamehr Ph.D.
Chief R&D Officer
Ms. Cindy R. Tahl
Gen. Counsel & Corporation Sec.
Mr. Jim Beitel M.B.A.
Senior Vice President of Corporation Devel.
Mr. Edward J. Dulac III
Chief Financial Officer
Dr. Mark Plavsic D.V.M., Ph.D.
Chief Technical Officer
Dr. Sarah Cooley
Senior Vice President of Clinical Translation
Mr. Brian T. Powl M.B.A., M.S.
Chief Commercial Officer
Dr. Jerome Bressi Ph.D.
Senior Vice President of Regulatory & Quality
Mr. J. Scott Wolchko
Founder, Chief Executive Officer, Pres & Director
Dr. Yu-Waye Chu M.D.
Chief Medical Officer
Chief R&D Officer
Ms. Cindy R. Tahl
Gen. Counsel & Corporation Sec.
Mr. Jim Beitel M.B.A.
Senior Vice President of Corporation Devel.
Mr. Edward J. Dulac III
Chief Financial Officer
Dr. Mark Plavsic D.V.M., Ph.D.
Chief Technical Officer
Dr. Sarah Cooley
Senior Vice President of Clinical Translation
Mr. Brian T. Powl M.B.A., M.S.
Chief Commercial Officer
Dr. Jerome Bressi Ph.D.
Senior Vice President of Regulatory & Quality
Mr. J. Scott Wolchko
Founder, Chief Executive Officer, Pres & Director
Dr. Yu-Waye Chu M.D.
Chief Medical Officer
How FATE did perform over past 52-week?
FATE's closing price is 84.85% higher than its 52-week low of $0.66 where as its distance from 52-week high of $1.94 is -37.11%.
How many employees does FATE have?
Number of FATE employees currently stands at 181.
Link for FATE official website?
Official Website of FATE is: https://www.fatetherapeutics.com
How do I contact FATE?
FATE could be contacted at phone 858 875 1800 and can also be accessed through its website. FATE operates from 12278 Scripps Summit Drive, San Diego, CA 92131, United States.
How many shares of FATE are traded daily?
FATE stock volume for the day was 2.04M shares. The average number of FATE shares traded daily for last 3 months was 1.65M.
What is the market cap of FATE currently?
The market value of FATE currently stands at $141.84M with its latest stock price at $1.22 and 116.26M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep